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PHeart Failure: Viewpoint
Hard Look at Angiotensin
eceptor Blockers in Heart Failure
hristian N. Gring, MD, Gary S. Francis, MD, FACC
leveland, Ohio
Multiple trials over the past several years have examined indications for angiotensin receptor
blockers (ARBs) in the treatment of left ventricular dysfunction, both acutely after myocardial
infarction and in chronic heart failure. Yet despite these data, there is still confusion regarding
the efficacy of ARBs as monotherapy in these patient populations, as well as the specific
indications for combination ARB/angiotensin-converting enzyme (ACE) inhibitor therapy.
We examine the key differences among the trials—including the ACE inhibitor dose, the
ARB and its dose, blood pressure reduction, and patient populations—to present our
perspective on ARB use, alone or in combination with ACE inhibitors, in patients with
chronic heart failure and post-myocardial infarction left ventricular dysfunction. We conclude
that ACE inhibitors remain the first-line therapy for left ventricular dysfunction. Angiotensin
receptor blockers should be reserved for monotherapy in ACE intolerant patients and for
combination therapy in symptomatic class II/III patients with chronic heart failure. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.07.044Coll Cardiol 2004;44:1841–6) © 2004 by the American College of Cardiology Foundation
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Vngiotensin-converting enzyme (ACE) inhibitors are a
ornerstone of therapy in patients with left ventricular (LV)
ystolic dysfunction, both immediately after myocardial
nfarction and long-term for heart failure. In patients with
ostmyocardial LV dysfunction, randomized, placebo-
ontrolled trials have consistently shown a substantial mor-
ality benefit of ACE inhibitor therapy. A systematic review
f these trials, whose mean duration of therapy was 31
onths, reported a 5.7% absolute risk reduction in mortality
ith ACE inhibitors (1). In chronic LV dysfunction, both
tudies Of Left Ventricular Dysfunction (SOLVD) (2) and
ooperative North Scandinavian Enalapril Survival study
CONSENSUS) (3) showed significant survival benefits
ith ACE inhibitor therapy. Thus, ACE inhibitors have
ecome the primary antagonist of the renin-angiotensin-
ldosterone system (RAAS) in the treatment of patients
ith heart failure.
Because of the impressive record of ACE inhibitors,
AAS antagonism has become a target for additional
harmacologic therapies—most notably with angiotensin
eceptor blockers (ARBs). The rationale for this class of
rugs is diverse, and includes prevention of “ACE-escape”
4,5) (which may portend a worse prognosis [6]), the
otential for synergism when used in combination with
CE inhibitors (7), more specific angiotensin II blockade
ia AT1 receptors, and the preservation of (theoretical)
enefits derived from unopposed AT2 receptor agonism (8).
he ACE-escape is defined as the gradual elevation of
erum angiotensin II and aldosterone levels, despite ongoing
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ccepted July 28, 2004.AAS inhibition with ACE inhibitors (9–11). Unopposed
T2 agonism may be a benefit of ARB therapy because,
lthough serum angiotensin II activates both AT1 and AT2
eceptors, ARBs only block the AT1 receptor. The AT1
eceptors mediate a host of potentially deleterious cardio-
ascular effects, including cell proliferation, vasoconstric-
ion, aldosterone secretion, and sodium reabsorption (8).
T2 receptors are not completely understood, and there are
o clinical data to prove that their unopposed activation is
eneficial, but they are generally believed to counter the
T1 response and lead to antiproliferative, antigrowth, and
asodilatory effects (8,12). Thus ARBs, either as mono-
herapy or in combination with ACE inhibitors, have
ecome a logical target of investigation for use in patients
ith heart failure.
Table 1 lists the key heart failure trials that have exam-
ned the use of ARBs compared with, or in combination
ith, ACE inhibitors (13–18). Tables 2 and 3 outline the
rial designs, treatment strategies, and major results. The
ssessment of Treatment with Lisinopril and Survival
ATLAS) trial (19) did not include ARBs, but is included
or reference and is discussed later. These trials have
enerated uncertainty about how ARBs should be used to
reat patients with heart failure, because they have not
onsistently shown benefit in patients with LV dysfunction.
or example, the Valsartan Heart Failure Trial (Val-HeFT)
nd the Candesartan in Heart Failure: Assessment of
eduction in Mortality and Morbidity-Added (CHARM-
dded) trial showed a reduction in cardiovascular morbidity
nd/or mortality with combination therapy compared with
CE inhibitor monotherapy, while Valsartan in Acute
yocardial Infarction Trial (VALIANT) did not; the
ALIANT trial and Losartan Heart Failure Survival study
ELITE-II) showed no difference between ACE inhibitors
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Angiotensin Receptor Blockers in Heart Failure November 2, 2004:1841–6nd ARBs, while Optimal Trial in Myocardial Infarction
ith the Angiotensin II Antagonist Losartan (OPTI-
AAL) suggested that ARBs were inferior to ACE
nhibitors.
These results, however, are not as inconsistent as they
nitially appear. The ARB trials have many similarities, but
iffer in their enrollment criteria, treatment strategies, and
nd points. We need to understand how these differences
ay have contributed to the disparate results and define
ore precisely which subgroups of patients with heart
ailure are likely to benefit most from ARB therapy. Spe-
ifically, we believe that an examination of the patient
opulations studied, ARB selection and dose, and blood
ressure reduction help to put the various trial results in
erspective. The trials also differ in ACE inhibitor dosing
ut, as discussed below, this fact may be less relevant.
ltimately, we must clarify the subgroups of patients who
hould be treated with ARBs, the doses that should be used,
nd the combination of additional medications that seem to
ffer the most benefit.
hronic heart failure or postinfarct LV dysfunction?
erhaps the most striking difference among trials is the
atient populations studied (Table 2). The CHARM-
dded, Val-HeFT, and ELITE-II trials all had similar
atient profiles: a predominance of class II to III patients
ith chronic heart failure, mean ejection fractions of 27% to
1%, and an approximate 60% incidence of ischemic car-
iomyopathy. The CHARM trial patients were likely
icker, because all class II enrollees had been recently
ospitalized with congestive symptoms. In contrast, the
atients enrolled in the VALIANT and OPTIMAAL trials
ad LV dysfunction in the setting of a recent myocardial
nfarction, a milder degree of heart failure (26% to 32% of
atients were Killip class I), and a mean ejection fraction of
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ARB  angiotensin receptor blocker
ATLAS  Assessment of Treatment with Lisinopril And
Survival trial
LV  left ventricle/ventricular
RAAS  renin-angiotensin-aldosterone system
SOLVD Studies Of Left Ventricular Dysfunction
Table 1. ARB Trial Abbreviations
CHARM-Added Candesartan
and Morb
Val-HeFT Valsartan H
CHARM-Alternative Candesartan
and Morb
ELITE-II Losartan He
OPTIMAAL Optimal Tri
Antagoni
VALIANT Valsartan inARB  angiotensin receptor blocker.t least 35%. Finally, by definition, patients had ischemic
eart disease.
The significance of these differences is not entirely clear,
s the patient populations did share a key demographic—
he majority had depressed ejection fractions and heart
ailure symptoms due to ischemic heart disease. In addition,
he overall event rates in the trials were similar. Annualized
otal mortality (9% to 10%) and cardiovascular mortality
8% to 9%) were comparable in the CHARM-Added and
ALIANT trials; the Val-HeFT trial reported a total
ortality of 9% as well, but did not examine a cardiovascular
ortality end point. As expected, annualized hospitaliza-
ions for heart failure in the CHARM-Added and Val-
eFT trials (both 8% to 9%) were higher than in the
ALIANT (6%) trial, whereas the VALIANT trial’s
yocardial infarction rate (2.9%) exceeded that of the
HARM-Added trial (1.6%). The event rates argue that
here is substantial overlap in the disease processes and
uggest that the patient populations homogenize over time.
Nevertheless, at the time of enrollment, patients were at
ifferent points in time along a lengthy disease continuum;
t is quite possible that patients with chronic heart failure
ave different morbidities and mortality, as well as different
esponses to therapies, than those with acute myocardial
nfarctions. Moreover, one cannot equate acute postmyo-
ardial infarction LV dysfunction, which is often transient,
ith established chronic heart failure. Finally, the myocar-
ial tissue RAAS may be quite different between these
atient groups, and may evolve as patients progress from
ecent myocardial infarction to worsening classes of chronic
eart failure (20).
The CHARM-Added studies and Val-HeFT provide
ompelling evidence that ARBs have a role in treating
atients with chronic heart failure, particularly in ACE-
ntolerant patients (CHARM-Alternative trial), and pa-
ients with relatively advanced heart failure. The data for
reating postmyocardial infarction LV dysfunction with
RBs are not as robust. In the VALIANT trial, ARB
onotherapy was equivalent to ACE inhibitor therapy—
gain supporting ARB use in ACE intolerant patients—but
ombination therapy was not beneficial. In the OPTI-
AAL trial, the ARB was inferior. The variation in patient
opulations studied likely explains some of the trials’ dis-
ordant results, and argues that ARB therapy works best in
eart Failure: Assessment of Reduction in Mortality
Added
ailure Trial
eart Failure: Assessment of Reduction in Mortality
Alternative
ailure Survival study
Myocardial Infarction with the Angiotensin II
artan
e Myocardial Infarction trialin H
idity-
eart F
in H
idity-
art F
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November 2, 2004:1841–6 Angiotensin Receptor Blockers in Heart Failureore symptomatic patients with long-term heart failure.
he discord between the OPTIMAAL and VALIANT
rials and the fact that the ELITE-II trial found a neutral
ffect of ARBs versus ACE inhibitors in patients with
hronic failure suggest that additional differences in the
rials may be impacting their results.
re all ARBs equal? The specific ARB used and its dose
ay provide a second explanation for the disparate results in
he trials. Clearly there are pharmacokinetic and pharma-
odynamic differences among ARBs, which may be clini-
ally relevant. Both candesartan and valsartan are dose-
ependent inhibitors of the AT1 receptor, with respective
eceptor affinities that are approximately 80 and 10 times
hat of losartan (7). Importantly, valsartan’s bioavailability
rops by 40% if it is taken with food (7). Losartan is a
elatively weaker receptor blocker than either valsartan or
andesartan, but its active metabolite is capable of an
nsurmountable receptor blockade (7). Clinically, these dif-
erences may have importance. Head-to-head blood pres-
ure studies have shown that valsartan 160 mg is superior to
osartan 100 mg daily, and that candesartan at doses of 8 mg
nd 16 mg daily is superior to losartan at 50 mg and 100 mg
aily (7).
The CHARM studies and the Val-HeFT trial both used
elatively potent ARBs in high doses, and demonstrated
eductions in hospital admissions for heart failure; the
HARM-Added trial showed a cardiovascular mortality
eduction. Conversely, the ELITE-II and OPTIMAAL
rials both used low-dose losartan versus high-dose capto-
ril, and neither study showed a benefit of ARB therapy
ver ACE inhibitor. These data suggest that 50 mg daily of
able 2. ARB Trial Designs
Trial n Population
HARM-Added 2,548 NYHA II–IV (24% II, 73%
Mean EF  28%
62% ischemic cardiomyopath
al-HeFT 5,010 NYHA II–IV (62% II, 36%
Mean EF  27%
57% ischemic cardiomyopath
HARM-Alternative 2,028 NYHA II–IV (48% II, 48%
Mean EF  30%
68% ischemic cardiomyopa
LITE-II 3,152 NYHA II–IV (52% II, 43%
Mean EF  31%
58% ischemic cardiomyopath
PTIMAAL 5,477 Post-MI LV dysfunction
32% Killip I, 57% Killip II
14% with LVEF 35%
ALIANT 14,703 Post-MI LV dysfunction
26% Killip I, 50% Killip II
Mean EF  35%
TLAS 3,164 NYHA II–IV (78% III)
Mean EF  23%
65% ischemic cardiomyopath
CE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; ATL
ejection fraction; LV  left ventricular; LVEF  left ventricular ejection fraction
id  three times a day.osartan may be too low. It is difficult to draw conclusions Vbout the relative strength of candesartan 32 mg versus
alsartan 160 mg twice a day.
oes the ACE inhibitor dose matter? A third difference
n the trials was variation in the ACE inhibitor and dose
sed. Although the protocols of the CHARM and Val-
eFT trials allowed the use of multiple ACE inhibitors, all
f the trials included patients receiving captopril. Thus, one
ight make some assumptions about whether ACE dose
mpacted the trial results. In the CHARM-Added and
al-HeFT trials, the two largest trials that showed ARB
enefit in patients with chronic heart failure, the average
ose of captopril was substantially lower than in the VAL-
ANT or OPTIMAAL trials, which found no incremental
enefit of ARB therapy compared to, or in combination
ith, ACE inhibitors (Table 2). The ATLAS study, how-
ver, provides compelling data that higher-dose ACE in-
ibitor is superior to lower-dose therapy. In this study,
hich compared low-dose versus high-dose lisinopril in
atients with chronic heart failure, the investigators re-
orted a 10% reduction in cardiovascular mortality (p 
.07) and a highly significant 24% reduction in hospitaliza-
ion for heart failure in the higher-dose group. There was no
ifference in the primary end point of all-cause mortality. In
imilar patient populations, the CHARM-Added and Val-
eFT trials both reported comparable results with combi-
ation ARB and ACE inhibitor therapy: highly significant
eductions in heart failure hospitalizations but no effect on
otal mortality. It should be noted, however, that the
HARM-Added trial’s reduction in cardiovascular mortal-
ty was significant. The ATLAS study results might suggest
hat ARBs showed benefit in the CHARM-Added and
Treatment Strategy
Candesartan 32 mg/day or placebo in addition to ACE inhibitor;
mean daily ACE doses  82 mg captopril, 17 mg enalapril
Valsartan 160 mg bid or placebo in addition to ACE inhibitor;
mean daily ACE doses  80 mg captopril, 17 mg enalapril
Candesartan 32 mg/day or placebo; all patients ACE intolerant
Losartan 50 mg qd vs. captopril 50 mg tid (no mean dose reported)
Losartan 50 mg qd vs. captopril 50 mg tid (mean 112 mg/day)
Valsartan 160 mg bid vs. captopril 50 mg tid  valsartan
80 bid vs. captopril 50 mg tid (mean  117 mg/day)
High-dose lisinopril (mean  33.2 mg/day) vs. low-dose
lisinopril (mean 4.5 mg/day)
Assessment of Treatment with Lisinopril and Survival trial; bid  twice a day; EF
myocardial in fraction; NYHA  New York Heart Association; qd  every day;III)
y
III)
y
III)
thy
III)
y
y
AS al-HeFT trials because patients were receiving submaxi-
Table 3. ARB Trial End Points and Results
Trial Primary/Secondary End Points Results BP Syst/Diast mm Hg
CHARM-Added Primary: cardiovascular death and CHF hospitalization 15% RRR in primary end point 4.6/3.0 mm Hg lower in combined arm
Secondary: cardiovascular morbidity and mortality composite 17% RRR in CV death
17% RRR in CHF admission
Val-HeFT Primary: all-cause mortality and cardiovascular combined morbidity No difference in mortality 5.2/1.3 mm Hg lower in combined arm
and mortality 13% RRR in morbidity and mortality, driven by
CHF reduction
CHARM-Alternative Primary: cardiovascular mortality or CHF hospitalization 23% RRR in primary end point 4.4/3.9 mm Hg lower with ARB
Secondary: composite cardiovascular morbidity and mortality 15% RRR in CV death
32% RRR in CHF admission
ELITE-II Primary: all-cause mortality No difference in any end point No difference
Secondary: sudden death/arrest No difference in CHF admissions
Tertiary: admissions for cardiovascular cause/all-cause mortality
OPTIMAAL Primary: all-cause mortality All outcomes favored captopril No difference
Secondary: sudden death/arrest Primary: 13% RRR (p  0.07)
Tertiary: fatal/nonfatal MI Secondary: 19% RRR (p  0.07)
Tertiary: no difference
CV death: 17% RRR (p  0.03)
CHF admit: 16% RRR (p  0.07)
VALIANT Primary: all-cause mortality No difference in primary or secondary end point By treatment arm (in mm Hg):
Secondary: CV morbidity and mortality ACE: 127/76
ARB/ACE: 125/75
ARB: 127/75
ATLAS Primary: all-cause mortality All results favored high-dose therapy 4.4/2.3 mm Hg reduction favoring high-dose therapy
Secondary: 1) cardiovascular mortality; 2) cardiovascular Primary: 8% RRR (p  0.128)
hospitalizations; 3) all-cause mortality  cardiovascular Secondary: 1) CV mortality: 10% RRR (p  0.07);
hospitalization; 4) Cardiovascular mortality  cardiovascular 2) CV hospitalizations: 16% RRR; 3) mortality/
hospitalization CV hospitalization: 8% RRR; 4) CV mortality/CV
hospitalization: 9% RRR, CHF hospitalization:
24% RRR
BP  blood pressure; CHF  congestive heart failure; CV  cerebrovascular; Diast  diastolic; MI  myocardial infarction; RRR  relative risk reduction; Syst  systolic. Other abbreviations as in Table 2.
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November 2, 2004:1841–6 Angiotensin Receptor Blockers in Heart Failureal doses of ACE inhibitor, and that maximizing the ACE
ose would have yielded similar results.
But two points argue that an insufficient ACE inhibitor
ose is not the whole answer. First, on a pathophysiologic
asis, one would expect that higher doses of ACE inhibitor
ould suppress angiotensin II levels more completely than
ower doses, thereby marginalizing any benefit of ARBs.
ultiple studies have failed to demonstrate this dose-
esponse relationship in patients with heart failure; rather,
ngiotensin II levels can vary markedly with any given ACE
nhibitor dose (6,10,11). These data suggest that higher
oses of ACE inhibitor do not predictably alter angiotensin
I levels, at least in the serum. Thus, if higher doses of ACE
nhibitor do confer additional benefits, they might be
ediated through other mechanisms, including alterations
n myocardial tissue ACE activity or extra-neurohormonal
athways.
Second, a substantial number of patients in both the
al-HeFT and CHARM-Added trials received relatively
igh doses of ACE inhibitors, and still showed benefit with
he addition of an ARB. Although captopril doses in these
tudies were moderate compared with postmyocardial in-
arction heart failure studies, the respective mean doses of
nalapril were 17 mg/day and 17.2 mg/day, which were
omparable with the mean dose in the SOLVD trial (16.6
g/day). Effectively, these patients were on evidence-based
oses of enalapril and still benefited with ARB therapy.
oreover, in the CHARM-Added trial, patients were
ivided into subgroups based on whether they were on
igh-dose, “target” daily doses of ACE inhibitor—for
xample, captopril 150 mg, or enalapril 20 mg. These
atients actually had a greater benefit with the addition of
andesartan than those on lower, non–evidence-based ACE
oses. The ATLAS study argues that ACE inhibitor dose is
mportant in the treatment of patients with chronic heart
ailure, and that underdosed patients have poorer outcomes.
ut it is difficult to argue that patients in the CHARM and
al-HeFT trials were underdosed with ACE inhibitors; we
ould assert that the variations in ACE inhibitor dosing
cross the trials did not substantially influence their results.
he importance of blood pressure reduction. A final
ossible explanation for the trials’ different outcomes is
hat the results reflect variations in blood pressure re-
ponse to therapy. Hypertension has long been recog-
ized as a risk factor for congestive heart failure and
schemic heart disease. Trials of essential hypertension,
hich typically have excluded patients with heart failure,
ave estimated that a 3 mm Hg reduction in systolic
lood pressure will decrease the risk of developing heart
ailure by 10% to 20% (21). A recent meta-analysis has
stimated that a long-term 5 mm Hg decline in diastolic
lood pressure would decrease ischemic heart disease
ortality by 30%, and even a 2-point reduction in systolic
lood pressure would yield a 7% decrement in ischemic
eart disease mortality (22).
The VALIANT, OPTIMAAL, and ELITE II trials did sot demonstrate ARB superiority, and none of these studies
ad substantial blood pressure differences among the treat-
ent arms (Table 3). Conversely, the CHARM-Added,
al-HeFT, and ATLAS trials had significant reductions in
lood pressure—4.4 to 5.2 mm Hg systolic and 1.3 to 3.9
m Hg diastolic. The CHARM-Added and ATLAS trials
eported decreases in cardiovascular mortality of 17% and
0%, respectively—reductions that could be largely ex-
lained on the basis of improved blood pressure alone. The
onsistent parallels between blood pressure reduction and
linical outcome argue for a possible causative relationship.
ecommendations. We now have multiple large, rigor-
usly performed studies that have investigated potential
ndications for ARBs in patients with heart failure. We
elieve several conclusions can be drawn. First, ACE
nhibitors, at evidence-based doses, continue to be first-line
rugs in the treatment of heart failure; no other RAAS
ntagonist has proven to be superior. Second, patients with
eart failure who are intolerant of ACE inhibitors should be
reated with ARBs. In ACE-intolerant patients with post-
yocardial infarction LV dysfunction, valsartan 320 mg is
ndicated. In patients with chronic heart failure, candesartan
2 mg daily is clearly beneficial. Additionally, subgroup
nalysis from the Val-HeFT trial suggests valsartan 320 mg
aily is valuable monotherapy in this population as well
23). The third conclusion is that the ARB dose is likely
ery important—a point that the ongoing Heart failure End
oint evaluation with the Angiotensin II Antagonist Losar-
an (HEAAL) study, which is comparing 50 mg versus 150
g daily of losartan in ACE-intolerant patients with heart
ailure, is addressing. Finally, combined therapy with ACE
nhibitor and ARB is without merit in acute, postinfarct LV
ysfunction.
Assessing the role of combined ACE/ARB therapy in
atients with chronic LV dysfunction remains challenging
ecause the data are incomplete. Asymptomatic and mini-
ally symptomatic patients have not been adequately stud-
ed. In symptomatic patients with heart failure, the Val-
eFT and CHARM-Added trials found that combined
herapy reduces hospitalizations for heart failure, but not
verall mortality. But the VALIANT trial showed no
ortality or morbidity benefit of combination therapy,
espite the fact that a significant portion of the VALIANT
rial patients, several months postinfarct, must have resem-
led the Val-HeFT or CHARM trial patients. Although
issue RAAS activity might initially be quite different
etween patient groups in the studies, it presumably evolves
s patients progress to symptomatic heart failure. This
volution is poorly characterized; neither its implications for
RB therapy nor its clinical relevance is entirely known. If
issue RAAS activity is a critical variable, we must deter-
ine how soon after an infarct ARB therapy should be
dded. We must also consider the possibility that the
enefits seen with combination therapy might not be due
pecifically to ARB therapy, but perhaps to blood pressure
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opulations.
Currently, the most compelling indication for combina-
ion therapy is in patients who remain symptomatic despite
tandard therapy including target doses of ACE inhibitors
nd beta-blockers. In the CHARM-Added trial, which
rovides the best evidence for combined therapy, 73% of
atients were class III, and all class II patients had at least
ne hospitalization for heart failure in the six months before
nrollment. Likewise, in subgroup analysis of the Val-
eFT trial, only class III and IV patients experienced
ignificant benefit with the addition of valsartan. Finally, a
ritical question that still needs further clarification is
hether an aldosterone antagonist or ARB should be added
rst to the medical regimens of highly symptomatic pa-
ients.
onclusions. Polypharmacy has become essential in the
anagement of heart failure, but it exposes patients to
ncreased costs and risks of drug-drug interactions. Thus, it
s paramount that we define clearly which patient groups
ill benefit most from therapy. Angiotensin receptor block-
rs are excellent therapeutic substitutes for ACE inhibitors,
ut they are costly: evidence-based doses of captopril (50 mg
hree times a day) or enalapril (10 mg twice a day) cost $10
o $15 per month, whereas the monthly target ARB doses in
he CHARM and VALIANT trials cost approximately $50
nd $100, respectively (24). From a public health perspec-
ive, therefore, ACE inhibitors are preferable. For the
reatment of chronic heart failure, combination therapy
hould be reserved for increasingly symptomatic patients
ecause the incremental value of ARBs when added to ACE
nhibitors and beta-blockers remains somewhat speculative
n class I and II patients. Even less clear are the risks and
enefits of triple RAAS therapy with ACE inhibitors,
RBs, and aldosterone antagonists; we recommend that
uch combinations be avoided until their safety and efficacy
re better established.
eprint requests and correspondence: Dr. Christian N. Gring,
/o Dr. Brian Griffin, Cleveland Clinic Foundation, Desk F-15,
500 Euclid Avenue, Cleveland, Ohio 44195. E-mail: gringc@
cf.org.
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